2025-14022Proposed RuleWallet

DEA proposes placing five obscure sedatives with names from a chemistry quiz

Published Date: 7/25/2025

Proposed Rule

Summary

The DEA wants to make five substances—clonazolam, diclazepam, etizolam, flualprazolam, and flubromazolam—officially illegal by putting them in Schedule I, the strictest drug category. This means anyone making, selling, or using these drugs will face serious legal consequences. Comments on this plan are open until August 25, 2025, so speak up before then!

Analyzed Economic Effects

4 provisions identified: 1 benefits, 3 costs, 0 mixed.

Permanent Schedule I listing and sanctions

DEA proposes to permanently add clonazolam, diclazepam, etizolam, flualprazolam, and flubromazolam (and their salts and isomers) to Schedule I. If finalized, anyone who manufactures, distributes, imports, exports, researches, conducts instructional activities or chemical analysis with, or possesses these substances would be subject to the CSA's Schedule I regulatory controls and administrative, civil, and criminal sanctions.

Mandatory DEA registration and controls for handlers

If finalized, any person who handles these five substances must be registered with DEA and comply with Schedule I requirements including security rules, labeling and packaging rules, manufacturing quotas, initial and biennial inventories, records and reporting, order-form requirements, and import/export compliance (citing 21 U.S.C. and 21 CFR authorities). The rule explicitly requires an initial inventory on the date a registrant first handles controlled substances and a new inventory every two years.

Very small number of suppliers affected

DEA identified 10 entities supplying these substances (per the SciFinder database), of which 2 have already registered with DEA; DEA expects only 8 additional suppliers would be impacted. DEA estimates affected suppliers would account for about 0.73 percent of small entities in the smallest NAICS industry listed (325412), and therefore concludes the rule would not have a significant economic impact on a substantial number of small entities.

No accepted medical use in United States

DEA (with HHS) states clonazolam, diclazepam, etizolam, flualprazolam, and flubromazolam are not approved by FDA and have no currently accepted medical use in treatment in the United States. HHS concluded these substances lack accepted safety for use under medical supervision.

Personalized for You

How does this regulation affect your finances?

Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Key Dates

Published Date
7/25/2025

Department and Agencies

Department
Independent Agency
Agency
Justice Department
Drug Enforcement Administration
Source: View HTML

Related Federal Register Documents

Previous / Next Documents

Back to Federal Register